Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Significant Palliative Benefits Following Therapy With Mifepristone for Advanced Treatment Resistant Small Cell Lung Cancer

JEROME H. CHECK, DIANE L. CHECK, TRINA PORETTA DO, MAYA SRIVASTAVA and ETHAN CHECK
Anticancer Research February 2024, 44 (2) 659-664; DOI: https://doi.org/10.21873/anticanres.16855
JEROME H. CHECK
1Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Cooper Medical School of Rowan University, Camden, NJ, U.S.A.;
2Cooper Institute for Reproductive Hormonal Disorders, P.C., Mt. Laurel, NJ, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: laurie{at}ccivf.com
DIANE L. CHECK
2Cooper Institute for Reproductive Hormonal Disorders, P.C., Mt. Laurel, NJ, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TRINA PORETTA DO
3Comprehensive Cancer and Hematology, Voorhees, NJ, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAYA SRIVASTAVA
4Department of Medicine, Division of Allergy and Immunology, State University of New York (SUNY) at Buffalo, Buffalo, NY, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ETHAN CHECK
2Cooper Institute for Reproductive Hormonal Disorders, P.C., Mt. Laurel, NJ, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 44 no. 2 659-664
DOI 
https://doi.org/10.21873/anticanres.16855
PMID 
38307551

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received December 5, 2023
  • Revision received January 13, 2024
  • Accepted January 15, 2024
  • Published online February 2, 2024.

Copyright & Usage 
Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Author Information

  1. JEROME H. CHECK1,2⇑,
  2. DIANE L. CHECK2,
  3. TRINA PORETTA DO3,
  4. MAYA SRIVASTAVA4 and
  5. ETHAN CHECK2
  1. 1Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Cooper Medical School of Rowan University, Camden, NJ, U.S.A.;
  2. 2Cooper Institute for Reproductive Hormonal Disorders, P.C., Mt. Laurel, NJ, U.S.A.;
  3. 3Comprehensive Cancer and Hematology, Voorhees, NJ, U.S.A.;
  4. 4Department of Medicine, Division of Allergy and Immunology, State University of New York (SUNY) at Buffalo, Buffalo, NY, U.S.A.
  1. Correspondence to: Jerome H. Check, MD, Ph.D., 7447 Old York Road, Melrose Park, PA 19027, U.S.A. Tel: +1 2156354400, e-mail: laurie{at}ccivf.com
View Full Text

Statistics from Altmetric.com

Cited By...

  • 3 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research: 44 (2)
Anticancer Research
Vol. 44, Issue 2
February 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Significant Palliative Benefits Following Therapy With Mifepristone for Advanced Treatment Resistant Small Cell Lung Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Significant Palliative Benefits Following Therapy With Mifepristone for Advanced Treatment Resistant Small Cell Lung Cancer
JEROME H. CHECK, DIANE L. CHECK, TRINA PORETTA DO, MAYA SRIVASTAVA, ETHAN CHECK
Anticancer Research Feb 2024, 44 (2) 659-664; DOI: 10.21873/anticanres.16855

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Significant Palliative Benefits Following Therapy With Mifepristone for Advanced Treatment Resistant Small Cell Lung Cancer
JEROME H. CHECK, DIANE L. CHECK, TRINA PORETTA DO, MAYA SRIVASTAVA, ETHAN CHECK
Anticancer Research Feb 2024, 44 (2) 659-664; DOI: 10.21873/anticanres.16855
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case Report
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Marked Palliative Benefits Seen With Treatment of Very Advanced Breast Cancer With the Progesterone Receptor Modulator Mifepristone
  • Good Quality 66.7% 5-year Overall Survival in Terminal Lung Cancer Patients Treated With Mifepristone
  • Google Scholar

More in this TOC Section

  • Antiemetic Efficacy of Aprepitant in Cisplatin–Gemcitabine Therapy for Biliary Tract Cancer: A Multicenter Study
  • Prognostic and Neurological Outcomes Following Surgery for Spinal NF2-Associated Ependymomas With Cysts
  • Prior Chlamydia trachomatis Infection and the Risk of Epithelial Ovarian Cancer and Borderline Ovarian Tumors
Show more Clinical Studies

Keywords

  • Small cell lung cancer
  • membrane progesterone receptor antagonists
  • mifepristone
  • advanced cancer
  • immuno-modulatory protein
  • the progesterone induced blocking factor
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire